Teva Pharmaceutical Industrieshas received US FDA approval and started shipping its fentanyl [transdermal] patches, in 25, 50, 75 and 100 μg/hour doses, AB-rated generic versions of Ortho-McNeil's (J&J) Duragesic. Generic fentanyl patches are already available in the US from other companies, including Mylan, Watson, Lavipharm and Actavis. Earlier this year, lots of Watson's and Actavis's versions were separately adversely affected by manufacturing issues. Teva's version is manufactured by Aveva Drug Delivery Systems, a division of Nitto Denko, which Teva describes as one of the world's largest manufacturers of, and pioneer in, drug-in-adhesive [transdermal] patch technology.
Teva launches transdermal fentanyl in the US
[C#198601169:Teva] Pharmaceutical Industrieshas received US FDA approval and started shipping its fentanyl [C#199901331:transdermal] patches, in 25, 50, 75 and 100 μg/hour doses, AB-rated generic versions of Ortho-McNeil's (J&J) Duragesic. Generic fentanyl patches are already available in the US from other companies, including Mylan, [C#198601285:Watson], [C#199902043:Lavipharm] and Actavis. Earlier this year, lots of [C#198601285:Watson]'s and Actavis's versions were separately adversely affected by manufacturing issues. [C#198601169:Teva]'s version is manufactured by Aveva Drug Delivery Systems, a division of [C#200101290:Nitto Denko], which [C#198601169:Teva] describes as one of the world's largest manufacturers of, and pioneer in, drug-in-adhesive [C#199901331:transdermal] patch technology.
More from Archive
More from Scrip
• By
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
• By
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
• By
Oral RNA splicing modulator has gone into a Phase II/III trial